Navigation Links
MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
Date:6/16/2009

Phase 3 PROTEGE ENCORE Clinical Trial Initiated

ROCKVILLE, Md. and INDIANAPOLIS, June 16 /PRNewswire/ -- MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the PROTEGE trial achieved its targeted patient enrollment. The trial is a pivotal Phase 2/3 clinical study evaluating teplizumab, an investigational compound under development for the treatment of individuals with recent-onset type 1 diabetes.

The PROTEGE trial is a randomized, double-blind, multi-center, multi-national, 4-arm, controlled study designed to evaluate the safety and efficacy of teplizumab in individuals with recent-onset type 1 diabetes, aged 8 to 35, who are within 12 weeks of their diagnosis. More than 530 individuals are enrolled in the study across 14 countries, including the United States. The primary composite endpoint for PROTEGE includes both the patient's total daily insulin usage and his/her HbA1c levels at 12 months. Secondary endpoints are evaluated at 24 months. Longer term safety and efficacy data from patients who complete the PROTEGE trial are being collected in a separate Phase 3 study called the PROTEGE Extension trial.

"The completion of enrollment of the PROTEGE study is an important milestone for MacroGenics and for the type 1 diabetes research community," stated Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "We appreciate the dedication of the patients, their caregivers and clinical investigators who helped advance this important late-stage clinical trial."

The companies also announced today that they have initiated the PROTEGE ENCORE trial, another Phase 3 global study of teplizumab in individuals with recent-onset type 1 diabetes, designed to capture patient-reported outcome measures in addition to safety and efficacy data. Information about the PROTEGE and PROTE
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
3. Study Showed Lillys GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients
4. Lilly Advances Second Alzheimers Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials
5. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
6. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
7. FDA Issues a Complete Response Letter for Lillys Olanzapine LAI for Treatment of Schizophrenia in Adults
8. Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
9. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
10. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
11. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire-iReach/ -- ChemImage founder and ... a scientific poster describing an innovative diagnostic procedure for ... Shedding New Light on Disease (SPEC) conference in Krakow, ... Treado,s poster entitled, "Development of in vitro Diagnostics for ... be discussed during the conference poster session on Tuesday, ...
(Date:8/19/2014)... -- Tokyo-based Atonarp Inc. announced today $8 million in ... Riverwood Ventures with participation from other co-investors.  The ... technology platform, which will enable a broad range ... & gas and healthcare industries for its initial ... with Atonarp in pursuing the commercialization of its ...
(Date:8/19/2014)... – a provider-led accelerator that puts the power of ... ­– announces Sutter Health, a not-for-profit health system in ... recent addition to the AVIA Innovator Network. ... focused helping patients navigate the healthcare system and enable ... so they work as a larger team for each ...
Breaking Medicine Technology:ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures 2AVIA and Sutter Health Join Forces to Address Healthcare's Most Pressing Challenges 2
... Md., Oct  27, 2011 Neuralstem, Inc. (NYSE Amex: ... in the ongoing safety trial to test its neuroregenerative small ... (MDD).  Phase Ia tested the drug in healthy volunteers for ... commence later this year, will test the safety and tolerability ...
... Oct. 27, 2011 Herborium Group, Inc., ... company, announced the following update today. ... stated: "These are truly exciting times for our Company. ... Bulletin Board exchange by maintaining Herborium, Current Information ...
Cached Medicine Technology:Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial 2Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial 3Herborium Group Shareholders Update 2Herborium Group Shareholders Update 3
(Date:8/20/2014)... August 20, 2014 GBK, the luxury lifestyle ... Emmy Award Nominees and Presenters at the annual GBK Gift ... and 23rd in Beverly Hills from 11am – 6pm. GBK ... music by DJ Morgan Hildebrand. , As always, GBK will ... feature several charities at the lounge. GO Campaign is a ...
(Date:8/20/2014)... Torrance, CA (PRWEB) August 20, 2014 ... Vision Expo West show to debut the new SL-17 ... to a 20,000 lux white LED source controlled by ... darkened examination rooms. The SL-17 uses commercially available AAA ... over the previous SL-15 design requiring batteries designed specifically ...
(Date:8/20/2014)... York (PRWEB) August 20, 2014 Over 31 ... Global Bureau of Disease, low back pain is the single ... most common reasons for missed work. Americans spend at least ... pain. , Most cases of back pain are not due ... (non-organic) origin. , For example, Pete, a busy accountant, had ...
(Date:8/19/2014)... As moms and dads prepare their children ... to the normal routine of dropping their little ones off ... MSc, RD encourages them to use the opportunity to ... , Yarker explains, “Kids have small tummies, short attention ... them junk food handouts, use snack time as another daily ...
(Date:8/19/2014)... Il (PRWEB) August 20, 2014 For ... allopathic medical world that chiropractic adjustments are dangerous and ... and this is why they do not recommend chiropractic ... more educated medical doctors do refer to chiropractors because ... However a statement regarding new research has popped up ...
Breaking Medicine News(10 mins):Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 2Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 3Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 4Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:Physical Therapists Learn to Relieve Low Back Pain 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 3Health News:Is It True That the Chiropractor Can Cause a Stroke? Dr. Harbison of AlignLife Wood River Speaks Up 2Health News:Is It True That the Chiropractor Can Cause a Stroke? Dr. Harbison of AlignLife Wood River Speaks Up 3Health News:Is It True That the Chiropractor Can Cause a Stroke? Dr. Harbison of AlignLife Wood River Speaks Up 4
... March 17 Baxa Corporation announces,the latest ... and Resources),Center course offerings. Safe Handling and ... nurses, pharmacists and physicians that prepare,handle or ... hands-on,experience with regulatory compliance and industry best ...
... Data could lead to new drugs to check vascular ... MONDAY, March 17 (HealthDay News) -- Researchers have pinpointed ... proliferation and leakiness behind most cases of blindness in ... of Utah study suggests a new therapeutic target for ...
... CARMEL, Ind., March 17 Conseco, Inc. (NYSE:,CNO) today ... Partners II,L.P. to nominate two of its representatives to ... been reviewing strategic,alternatives and has engaged the investment banking ... CEO Jim Prieur said, "We share with Steel Partners, ...
... March 17 ANSYS, Inc.,(Nasdaq: ANSS ), ... to optimize product development processes, today announced it ... exhibit at the Carnegie Museum of,Natural History in ... the,world to feature scientifically accurate, immersive environments that ...
... Echocardiographic Data Safety Monitoring Board, Review ... SAN DIEGO, March 17 Arena ... that following a planned review by an,independent ... is,continuing BLOOM (Behavioral modification and Lorcaserin for ...
... California public payers now cover Monogram,s Trofile assay, ... Biosciences, Inc. (Nasdaq: MGRM ) today announced ... and,reimbursement for Monogram,s Trofile Assay., Medi-Cal is ... provide essential medical care and services to individuals,or ...
Cached Medicine News:Health News:Baxa Corporation Announces Safe Handling and Preparation of Hazardous Drugs Course Offering at its STAR Center Training Facility 2Health News:Baxa Corporation Announces Safe Handling and Preparation of Hazardous Drugs Course Offering at its STAR Center Training Facility 3Health News:Study Finds Potential Cause of Age-Related Macular Degeneration 2Health News:Study Finds Potential Cause of Age-Related Macular Degeneration 3Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 2Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 3Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 2Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 3Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 4Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 5Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 6Health News:California Medicaid Establishes Coverage for Trofile(TM) 2Health News:California Medicaid Establishes Coverage for Trofile(TM) 3Health News:California Medicaid Establishes Coverage for Trofile(TM) 4
... Tips are available as both regular and ... by gamma-rays for more efficient sterilization and ... specifying the date of irradiation. Sterilized Diamond ... to autoclave. SterilPack Diamond Tips are wrapped ...
This large 1000 L tip makes pipetting fragile cells, genomic DNA, and viscous samples easy. Perfect for cell culture laboratories....
This 1000 L tip is the equivalent to the "Blue" tips and fits nearly every manufacturer's 1000 L pipettor....
Conducting disposable filter-tips....
Medicine Products: